GenMark Diagnostics (GNMK) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Equities close higher as softer jobs data quiets rate-hike expectations
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
GenMark Diagnostics Reports Q2 Financial Results
July 28, 2016 4:09 PM EDT
Second Quarter Revenue Increased 64% Versus Prior Year to $12.5
million
ePlex® Systems Installed at
Twelve European Customers
ePlex FDA Submission Expected in
Fourth Quarter
CARLSBAD, Calif.--(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the second quarter ended June 30, 2016.
Revenue for the second quarter of 2016 was $12.5 million, an increase of 64% over the prior year period.
Gross profit for the second quarter of 2016 was $7.8 million, or 62% of revenue, compared with $4.4... More
